ClinicalTrials.gg
TerminatedNCT02720120Updated Mar 28, 2016

A Study of Ocrelizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA)

A Phase 1/2 interventional study of Ocrelizumab and Placebo in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Terminated at 49 sites in 8 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-03-28.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The overall benefit risk profile of ocrelizumab was not favorable in RA

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Hoffmann-La Roche.

Enrollment
61st of 141
175 · median 132
Started
2005
with 13 others
Phase 1/2
2 of 219
none open now
Registered
209th of 219
by date

Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 61st largest by enrollment of the 141 interventional ones that give a count, is one of 14 that started in 2005, is one of 2 in phase 1/2, and was the 209th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study is in two parts and will evaluate the safety, tolerability and efficacy of escalating single intravenous (IV) doses of ocrelizumab compared with placebo in combination with methotrexate in participants with moderate to severe RA. Part 1 is the dose-escalation study, at one of the following dose levels of ocrelizumab [400, 1000, 1500, and 2000 milligrams (mg)]. In Part 2, participants will be randomized to explore tolerability and efficacy of doses which have been shown to be tolerated in Part 1.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate to severe RA for at least 6 months
  • Positive serum rheumatoid factor (>/= 20 international units per milliliter)
  • Current treatment with RA on an outpatient basis
  • Treatment failure with one disease modifying anti-rheumatic drug (DMARD) or biologic, but have not failed more than six of these agents including methotrexate
  • Current treatment with methotrexate for at least 12 weeks, at a stable dose
  • Use of highly effective .

Exclusion criteria

Exclusion Criteria:

  • Rheumatic disease or inflammatory joint disease, other than RA
  • Concurrent treatment with any disease-modifying anti-rheumatic drug (DMARD) (other than methotrexate) or any anti-tumor necrosis factor (TNF) -alfa or other biologic therapy
  • Treatment with any other drug within 4 weeks of screening
  • Previous treatment with cell-depleting therapies, IV gamma-globulin, intra-articular or parenteral , and receipt of live/attenuated vaccine prior to screening
  • Previous treatment with rituximab or any other anti-cluster of differentiation 20 (CD20) agent
  • History of severe allergic or anaphylactic reactions to humanized monoclonal antibodies
  • Known active bacterial, viral or fungal infections
  • History of active tuberculosis and primary or secondary immunodeficiency
  • History of concomitant diseases such as cardiovascular disease, nervous system, pulmonary disease, renal, hepatic, endocrine or gastrointestinal disorders
  • Pregnancy or lactation.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Part 1: Ocrelizumab 1000 mg

    Participants will receive single IV infusion of ocrelizumab 1000 mg.

    Drug: Ocrelizumab

  • Experimental
    Part 1: Ocrelizumab 1500 mg

    Participants will receive single IV infusion of ocrelizumab 1500 mg.

    Drug: Ocrelizumab

  • Experimental
    Part 1: Ocrelizumab 2000 mg

    Participants will receive single IV infusion of ocrelizumab 2000 mg.

    Drug: Ocrelizumab

  • Experimental
    Part 1: Ocrelizumab 400 mg

    Participants will receive single IV infusion of ocrelizumab 400 milligrams (mg)

    Drug: Ocrelizumab

  • Placebo comparator
    Part 1: Placebo

    Participants will receive single IV infusion of placebo matched to ocrelizumab.

    Drug: Placebo

  • Experimental
    Part 2: Ocrelizumab 1000 mg

    Participants will receive single IV infusion of ocrelizumab 1000 mg.

    Drug: Ocrelizumab

  • Experimental
    Part 2: Ocrelizumab 1500 mg

    Participants will receive single IV infusion of ocrelizumab 1500 mg.

    Drug: Ocrelizumab

  • Experimental
    Part 2: Ocrelizumab 400 mg

    Participants will receive single IV infusion of ocrelizumab 400 mg.

    Drug: Ocrelizumab

Interventions

  • Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.

    Also known as: RO4964913, rhuMAb 2H7, PRO70769

  • DrugPlacebo

    Participants will receive single IV infusion of placebo.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events (AEs) or Serious AEs (SAEs)

    Time frame: Baseline up to approximately 7.25 years

  2. Percentage of Participants with Anti-Ocrelizumab Antibodies

    Time frame: Baseline up to approximately 7.25 years

Secondary outcomes

  1. Percentage of Participants with American College of Rheumatology (ACR) 20%, 50%, and 70% (ACR20/50/70) Response at Week 24

    Time frame: Week 24

  2. Disease Activity Score at Week 24

    Time frame: Week 24

  3. Percentage of Participants achieving European League Against Rheumatism (EULAR) Response at Week 24

    Time frame: Week 24

  4. Maximum Plasma Concentration (Cmax) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  5. Time to Blood B-Cell Depletion

    Time frame: Baseline up to approximately 7.25 years

  6. Terminal Elimination Half-Life (t1/2) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  7. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  8. Area Under the Plasma Concentration-Time Curve From Time 0 to Last Quantifiable Concentration AUC(0-last) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  9. Time to Maximum Observed Plasma Concentration (Tmax) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  10. Terminal Rate Constant of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  11. Systemic Clearance (CL) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  12. Mean Residence Time (MRT) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  13. Steady State Volume of Distribution (Vss) of Ocrelizumab

    Time frame: Pre-infusion (0 hours); 30 minutes post infusion on Day 1; Weeks 1, 2, 4, 6, 8, 12, 16, 20, 24 (up to Week 24), and Weeks 36, 48 (Post Week 24)

  14. Duration of Blood B-Cell Depletion

    Time frame: Baseline up to approximately 7.25 years

07

Study locations

49 sites
  • Darlinghurst, New South Wales 2010, Australia
  • Adelaide, South Australia 5041, Australia
  • Melbourne, Victoria 3004, Australia
  • Perth, Western Australia 6979, Australia
  • Gent, 9000, Belgium
  • Leuven, 3000, Belgium
  • Calgary, Alberta T2N 4Z6, Canada
  • Edmonton, Alberta T6G 2S2, Canada
  • London, Ontario N6A 4V2, Canada
  • Toronto, Ontario M4N 3M5, Canada
  • Toronto, Ontario M5G 1X5, Canada
  • Toronto, Ontario M5T 2S8, Canada
  • Quebec City, Quebec G1V 3M7, Canada
  • Sherbrooke, Quebec J1H 5N4, Canada
  • Amsterdam, 1105 AZ, Netherlands
  • Auckland City, 0620, New Zealand
  • Auckland, 2025, New Zealand
  • Moscow, 115522, Russian Federation
  • Moscow, 119049, Russian Federation
  • Moscow, 129110, Russian Federation
  • Moscow, 129327, Russian Federation
  • Saint-Petersburg, 195067, Russian Federation
  • St Petersburg, 194291, Russian Federation
  • St. Petersburg, 190068, Russian Federation
  • Cádiz, Cadiz 11009, Spain
  • Santiago de Compostela, La Coruña 15706, Spain
  • Alcorcon, Madrid 28922, Spain
  • La Laguna, Tenerife 38320, Spain
  • Barcelona, 08025, Spain
  • Barcelona, 08035, Spain
  • Granada, 18003, Spain
  • Madrid, 28041, Spain
  • Madrid, 28222, Spain
  • Madrid, 28935, Spain
  • Sevilla, 41014, Spain
  • Valencia, 46017, Spain
  • Aberdeen, AB25 2ZD, United Kingdom
  • Cambridge, CB2 2QQ, United Kingdom
  • Derby, DE22 3NE, United Kingdom
  • Leeds, LS1 3EX, United Kingdom
  • Liverpool, L9 7AL, United Kingdom
  • London, E11 1NR, United Kingdom
  • London, SE1 9RT, United Kingdom
  • Maidstone, ME16 9QQ, United Kingdom
  • Newcastle Upon Tyne, NE1 4LP, United Kingdom
  • Norwich, NR4 7UY, United Kingdom
  • Salford, M6 8HD, United Kingdom
  • Torquay, TQ2 7AA, United Kingdom
  • West Midlands, M41 5SL, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2005, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2016
First posted
Mar 25, 2016
Start
Oct 2005
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Last update
Mar 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02720120
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
Oct 2005
Primary completion
Feb 2013
Completion
Feb 2013
Last update
Mar 28, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion